Chronic Heart Failure
Biopharmaceutical company reports results of treatment for chronic heart failure
Published in Biotech Business Week, July 25th, 2005
The trial results failed to demonstrate a statistically significant benefit for any of the three coprimary endpoints. The trials met the prespecified safety endpoint by demonstrating no significant difference in mortality between the enoximone and placebo groups.
Based on these results, the company will terminate development of enoximone capsules and dedicate all resources to the development of its two other late-stage clinical programs, ambrisentan for the treatment of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Business Update
Gene-based company to list on NASDAQ - Cardiovascular Disease
FM-VP4 toxicity study complete - Cardiovascular Surgery
Research demonstrates potential of TMR Plus gene therapy - Drug Development
Phase III study to evaluate first-in-class drug to treat cardiogenic shock - Mergers & Acquisitions
Microscience, a U.K.-based vaccine company, acquired - Respiratory Medicine
Promising phase II data with inhaled anticholinergic LAS34273 reported - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
